Data from a 10-year follow-up study confirm that the Escherichia coli-produced HPV-16/18 bivalent vaccine (Cecolin) elicits sustained antibody responses and confers durable protection against HPV 16/18 associated high-grade cervical, vulvar or vaginal lesions and persistent infections for a minimum of 10 years post-vaccination.

On September 9, 2025, Xiamen Innovax Biotech Co., Ltd. (Innovax), a leading biotech company in vaccine innovation, announced a major public health milestone with the administration of the first dose of its Cecolin® 9 (HPV 9-valent vaccine) at the Shitang Community Health Service Center in Haicang District, Xiamen. This landmark event marks the official launch of China’s first independently developed HPV 9-valent vaccine, offering a new layer of protection for females aged 9 to 45 against cervical cancer.

Data from the three-year follow-up study confirm that Cecolin 9, the E. coli-produced HPV 9-valent vaccine co-developed by Innovax and Xiamen University, maintains non-inferior type-specific plateau antibody levels compared to a marketed HPV 9-valent vaccine in Chinese women aged 18-26 years, supporting its potential for enduring protection against targeted HPV types.

Cecolin®9, the world’s second HPV 9-valent vaccine, has received China’s Biological Products Batch Release Certificate from NIFDC in August, 2025,—officially launching in China and marking the start of its global journey.

On July 9th, at the "High-Level Meeting on Thailand's 2026 HPV Vaccination Program" hosted by Thai Department of Juvenile Observation & Protection (DJOP), Thai Ministry of Justice and the Thai Gynecologic Cancer Society (TGCS), INNOVAX participated as a key partner and, join hands with Global Biotech Products (GBP) in this program as a CSR program, announced a donation of special funding and bivalent HPV vaccine—Cecolin®, to support cervical cancer prevention efforts for Thai youth.

On June 5, 2025, the China National Intellectual Property Administration (CNIPA) announced the winners of the 25th China Patent Award.The invention patent "Truncated L1 Protein of Human Papillomavirus Type 16" (Patent No. ZL 200810093816.8), jointly held by Xiamen Innovax Biotech Co., Ltd. and Xiamen University, was honored with the China Patent Gold Award. The inventors of this Gold Award-winning patent are Gu Ying, Li Shaowei, Wei Minxi, Xian Yangling, Luo Wenxin, and Xia Ningshao.